A Safer Autoimmunity Treatment Blunts Disease Activity in Rheumatoid Arthritis (2 of 2) (VIDEO)

American Association for the Advancement of Science (AAAS)

Caption

Jorn Drappa, senior author of the new study, responding to the question, "What promise does targeting CD40L potentially offer over therapies that target TNFa and IL-17, which are currently under clinical development?". This material relates to a paper that appeared in the Apr. 24, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by J.L. Karnell at Viela Bio in Gaithersburg, MD; and colleagues was titled, "A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity."

Credit

Jorn Drappa

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.